Atinvicitinib

Atinvicitinib is a veterinary medicinal product under investigation for the treatment of atopic dermatitis in dogs.^[1] Atinvicitinib is a selective Janus kinase (JAK) inhibitor, highly selective for Janus kinase 1 (JAK1). It inhibits the function of a variety of cytokines involved in itch and inflammation, as well as cytokines involved in allergy, that are dependent on JAK1 enzyme activity.^[1] Reduction of allergy mediated inflammation, which is dependent on JAK1 enzyme activity, leads to a reduction of inflammation associated white blood cell counts (within the reference range).^[1]

ATCvet code

• QD11AH93 (WHO)

CAS Number

• 2169273-59-8

PubChem CID

• 135138184

ChemSpider

• 76784061

Quick facts Clinical data, ATCvet code ...

Atinvicitinib

Clinical data
ATCvet code	QD11AH93 (WHO)
Identifiers
IUPAC name 1-[(3R,4S)-4-cyanooxan-3-yl]-3-[(2-fluoro-6-methoxypyridin-4-yl)amino]pyrazole-4-carboxamide
CAS Number	2169273-59-8
PubChem CID	135138184
ChemSpider	76784061
UNII	C238YE66P2
ChEMBL	ChEMBL4066193
Chemical and physical data
Formula	C16H17FN6O3
Molar mass	360.349 g·mol−1
3D model (JSmol)	Interactive image
SMILES COc1cc(Nc2nn([C@H]3COCC[C@@H]3C#N)cc2C(N)=O)cc(F)n1
InChI InChI=1S/C16H17FN6O3/c1-25-14-5-10(4-13(17)21-14)20-16-11(15(19)24)7-23(22-16)12-8-26-3-2-9(12)6-18/h4-5,7,9,12H,2-3,8H2,1H3,(H2,19,24)(H,20,21,22)/t9-,12+/m1/s1 Key:PRQMBGDYXWVEHE-SKDRFNHKSA-N

Close